Delta plus variant is at a very fast spread in the world now almost reported in 135 countries. It is actually a SARS-Cov-2 variant which has lead to second wave in India with high transmissibility and is named as delta variant B.1.617.2. And delta has further mutated delta AY.1,AY.2 and AY.3.From India and in nearly 20 other countries the AY.1 has been detected in April 2021 as per pre-print study reports.
As per a study published in biorvix by ICMR,Bharath Biotech’s covid-19 vaccine Covaxin(BBV15) is effective against Delta plus(AY.1) variant of coronavirus. After full dosage with BBV152 covaxin ,covid-19 recovered cases with full vaccine doses has shown a breakthrough immunisation against Delta (AY.1) and B.1.617.3 by testing the IgG antibody titer and neutralising potential of sera of covid-19 naive individuals with full doses of BBV152 vaccine.
As per clinical phase 3 trial which is a double-blind, randomised and multicentre,65.2 percent protection against Delta variant B.1.617.2 was shown when mass immunisation was done with Covaxin(a whole virion inactivated SARS CoV-2 vaccine).And also against symptomatic Covid-19 the Covaxin is 77.8 percent effective as reported in final Phase 3 trials on July 3rd conducted by Bharath Biotech.
